Austin, Texas, United States, November 5th, 2026, NewsDirect
- The scale of the need for neurological solutions is enormous; the World Health Organization reports that more than three billion people live with a neurological condition.
- Quantum focuses on neurodegenerative, metabolic and alcohol misuse disorders, pursuing a strategy that pairs pharmaceutical research with commercialization partnerships and licensing structures designed to support multiple potential revenue streams.
- The most advanced piece of the neurodegenerative strategy is Lucid-MS, a patented new chemical entity designed to address demyelination.
Brain disorders touch more lives than almost any other area of medicine, yet they remain among the hardest to treat. Quantum BioPharma (NASDAQ: QNTM) is taking on that challenge with a diversified strategy that spans clinical drug development, consumer wellness and royalty-based partnerships.
The scale of the need is enormous. The World Health Organization reported that more than three billion people were living with a neurological condition in 2021. The overall burden of disability, illness and premature death from these conditions rose…
NOTE TO INVESTORS: IBN is a multifaceted financial news, content creation and publishing company utilized by both public and private companies to optimize investor awareness and recognition. For more information, please visit https://www.IBN.ai
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer
The latest news and updates relating to QNTM are available in the company’s newsroom at https://ibn.fm/QNTM
Corporate Communications
IBN
Austin, Texas
512.354.7000 Office
Contact
IBN
www.InvestorBrandNetwork.com
[email protected]